The Department of Trade and Industry (DTI) would like to limit to a maximum of 21-day processing of permits for proponents of vaccine manufacturing projects and to appoint a focal person at the Food and Drugs Administration (FDA) to ensure no red tape for this priority project, which President Duter
Food and Drug Administration (FDA)
“Ang FDA will cooperate fully with the authorities sa pag-investigate nito para makita po natin kung meron nga pong problema (The FDA will cooperate fully with the authorities in investigating this, so we can determine if there are problems),” said FDA Director-General Rolando Enrique Domingo in a radio interview on Wednesday, May 12.
Domingo said that his agency’s legal service office is currently looking at the matter.
“Yung aming legal service ngayon ay tumutulong na rin na hanapin itong mga applications na ito para malaman kung may pagkukulang man o may problema talaga at hindi naaaksyunan (Our legal service is now also helping in finding these applications to know if there are any shortcomings or problems, or inactions),” he said.
DTI s Lopez tells oxygen industry to prepare for demand surge bworldonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bworldonline.com Daily Mail and Mail on Sunday newspapers.
Published May 11, 2021, 3:57 PM
The Anti-Red Tape Authority (ARTA) has issued a show-cause order to a Food and Drug Administration (FDA) office for sitting on over 600 drug applications filed since 2014 despite completeness of submission of various pharmaceutical companies.
ARTA Investigation Enforcement and Litigation Director Jedrek Ng on Tuesday, May 11, ordered FDA Center for Drug Regulation and Research (CDRR) Director IV Jesusa Cirunay to “explain why no administrative or criminal case should be filed” against her.
ARTA’s action stemmed from the 23 affidavits of several pharmaceutical companies detailing the alleged delays committed by FDA-CDRR on their applications filed as far back as 2014 or so.
FDA official asked to explain 600 pending drug applications
enablePagination: false
endIndex:
Metro Manila (CNN Philippines, May 11) – The Anti-Red Tape Authority issued on Tuesday a show-cause order against a Food and Drug Administration official for 600 drug applications pending in her office.
ARTA ordered FDA Center for Drug Regulation and Research (FDA-CDRR) Director Jesusa Cirunay to explain why the drug applications remain pending despite the complete submission of requirements by involved pharmaceutical firms.
The complaint stemmed from the 23 affidavits of several pharmaceutical companies which detailed the alleged delays committed by FDA-CDRR on their applications filed since 2014.
na to di ito kumplikado. Ito yung mga aplikasyong for automatic renewal.